AI Article Synopsis
- Serial analysis of circulating tumor DNA (ctDNA) is becoming a key biomarker for monitoring and personalizing cancer treatment, particularly in metastatic cases like lung cancer.
- In nonmetastatic disease, detecting ctDNA from minimal residual disease (MRD) poses significant technical challenges, despite advances in tumor genotyping and ctDNA profiling showing potential in predicting recurrence.
- The discussion covers the current progress, existing limitations, and future opportunities for using ctDNA both in guiding targeted therapies in metastatic cancer and in managing adjuvant treatment for nonmetastatic patients.
Article Abstract
Serial analysis of circulating tumor DNA (ctDNA) over the disease course is emerging as a prognostic, predictive and patient-monitoring biomarker. In the metastatic setting, several multigene ctDNA assays have been approved or recommended by regulatory organizations for personalized targeted therapy, especially for lung cancer. By contrast, in nonmetastatic disease, detection of ctDNA resulting from minimal residual disease (MRD) following multimodal treatment with curative intent presents major technical challenges. Several studies using tumor genotyping-informed serial ctDNA profiling have provided promising findings on the sensitivity and specificity of ctDNA in predicting the risk of recurrence. We discuss progress, limitations and future perspectives relating to the use of ctDNA as a biomarker to guide targeted therapy in metastatic disease, as well as the use of ctDNA MRD detection to guide adjuvant treatment in the nonmetastatic setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2023.103540 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!